FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015389972> ?p ?o ?g. }

• W3015389972 endingPage "e000213" @default.
• W3015389972 startingPage "e000213" @default.
• W3015389972 abstract "Background First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the advent of target-specific and highly active immunotherapeutics, both the Food and Drug Administration and the European Medicines Agency have provided guidance that recommend determining a safe starting dose based on a minimum anticipated biological effect level (MABEL) approach. Methods We recently developed a T cell activating bispecific antibody that effectively treats orthotopic patient-derived malignant glioma and syngeneic glioblastoma in mice (hEGFRvIII:CD3 bi-scFv). hEGFRvIII:CD3 bi-scFv is comprized of two single chain antibody fragments (bi-scFvs) that bind mutant epidermal growth factor receptor variant III (EGFRvIII), a mutation frequently seen in malignant glioma, and human CD3ε on T cells, respectively. In order to establish a FIH dose, we used a MABEL approach to select a safe starting dose for hEGFRvIII:CD3 bi-scFv, based on a combination of in vitro data, in vivo animal studies, and theoretical human receptor occupancy modeling. Results Using the most conservative approach to the MABEL assessment, a dose of 57.4 ng hEGFRvIII:CD3 bi-scFv/kg body weight was selected as a safe starting dose for a FIH clinical study. Conclusions The comparison of our MABEL-based starting dose to our in vivo efficacious dose and the theoretical human receptor occupancy strongly supports that our human starting dose of 57.4 ng hEGFRvIII:CD3 bi-scFv/patient kg will be safe." @default.
• W3015389972 created "2020-04-17" @default.
• W3015389972 creator A5015860179 @default.
• W3015389972 creator A5037596103 @default.
• W3015389972 creator A5039488761 @default.
• W3015389972 creator A5050795555 @default.
• W3015389972 creator A5074135304 @default.
• W3015389972 creator A5090604007 @default.
• W3015389972 date "2020-04-01" @default.
• W3015389972 modified "2023-10-16" @default.
• W3015389972 title "First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach" @default.
• W3015389972 cites W1845477376 @default.
• W3015389972 cites W1981952228 @default.
• W3015389972 cites W2001700978 @default.
• W3015389972 cites W2005008347 @default.
• W3015389972 cites W2012811079 @default.
• W3015389972 cites W2050869931 @default.
• W3015389972 cites W2051837145 @default.
• W3015389972 cites W2080341180 @default.
• W3015389972 cites W2090831304 @default.
• W3015389972 cites W2094950761 @default.
• W3015389972 cites W2169770594 @default.
• W3015389972 cites W2205491921 @default.
• W3015389972 cites W2469610249 @default.
• W3015389972 cites W2486542402 @default.
• W3015389972 cites W2555713829 @default.
• W3015389972 cites W2560270282 @default.
• W3015389972 cites W2591709377 @default.
• W3015389972 cites W2752698292 @default.
• W3015389972 cites W2777630487 @default.
• W3015389972 cites W2791483720 @default.
• W3015389972 cites W2794420673 @default.
• W3015389972 cites W2802463738 @default.
• W3015389972 cites W2804772768 @default.
• W3015389972 cites W2884450301 @default.
• W3015389972 cites W2889712129 @default.
• W3015389972 cites W2893003701 @default.
• W3015389972 cites W2948141873 @default.
• W3015389972 cites W2954493613 @default.
• W3015389972 cites W4214872569 @default.
• W3015389972 doi "https://doi.org/10.1136/jitc-2019-000213" @default.
• W3015389972 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7254109" @default.
• W3015389972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32273346" @default.
• W3015389972 hasPublicationYear "2020" @default.
• W3015389972 type Work @default.
• W3015389972 sameAs 3015389972 @default.
• W3015389972 citedByCount "16" @default.
• W3015389972 countsByYear W30153899722020 @default.
• W3015389972 countsByYear W30153899722021 @default.
• W3015389972 countsByYear W30153899722022 @default.
• W3015389972 countsByYear W30153899722023 @default.
• W3015389972 crossrefType "journal-article" @default.
• W3015389972 hasAuthorship W3015389972A5015860179 @default.
• W3015389972 hasAuthorship W3015389972A5037596103 @default.
• W3015389972 hasAuthorship W3015389972A5039488761 @default.
• W3015389972 hasAuthorship W3015389972A5050795555 @default.
• W3015389972 hasAuthorship W3015389972A5074135304 @default.
• W3015389972 hasAuthorship W3015389972A5090604007 @default.
• W3015389972 hasBestOaLocation W30153899721 @default.
• W3015389972 hasConcept C114684123 @default.
• W3015389972 hasConcept C126322002 @default.
• W3015389972 hasConcept C150903083 @default.
• W3015389972 hasConcept C159654299 @default.
• W3015389972 hasConcept C167672396 @default.
• W3015389972 hasConcept C170493617 @default.
• W3015389972 hasConcept C202751555 @default.
• W3015389972 hasConcept C203014093 @default.
• W3015389972 hasConcept C207001950 @default.
• W3015389972 hasConcept C2778227246 @default.
• W3015389972 hasConcept C2779438470 @default.
• W3015389972 hasConcept C3020495827 @default.
• W3015389972 hasConcept C502942594 @default.
• W3015389972 hasConcept C542903549 @default.
• W3015389972 hasConcept C55493867 @default.
• W3015389972 hasConcept C71924100 @default.
• W3015389972 hasConcept C86803240 @default.
• W3015389972 hasConcept C8891405 @default.
• W3015389972 hasConcept C98274493 @default.
• W3015389972 hasConceptScore W3015389972C114684123 @default.
• W3015389972 hasConceptScore W3015389972C126322002 @default.
• W3015389972 hasConceptScore W3015389972C150903083 @default.
• W3015389972 hasConceptScore W3015389972C159654299 @default.
• W3015389972 hasConceptScore W3015389972C167672396 @default.
• W3015389972 hasConceptScore W3015389972C170493617 @default.
• W3015389972 hasConceptScore W3015389972C202751555 @default.
• W3015389972 hasConceptScore W3015389972C203014093 @default.
• W3015389972 hasConceptScore W3015389972C207001950 @default.
• W3015389972 hasConceptScore W3015389972C2778227246 @default.
• W3015389972 hasConceptScore W3015389972C2779438470 @default.
• W3015389972 hasConceptScore W3015389972C3020495827 @default.
• W3015389972 hasConceptScore W3015389972C502942594 @default.
• W3015389972 hasConceptScore W3015389972C542903549 @default.
• W3015389972 hasConceptScore W3015389972C55493867 @default.
• W3015389972 hasConceptScore W3015389972C71924100 @default.
• W3015389972 hasConceptScore W3015389972C86803240 @default.
• W3015389972 hasConceptScore W3015389972C8891405 @default.
• W3015389972 hasConceptScore W3015389972C98274493 @default.
• W3015389972 hasFunder F4320337351 @default.

• next